Fate Therapeutics Analyst Ratings
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $5
Fate Therapeutics: Hold Rating Amid Financial Stability and Upcoming Milestones
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Fate Therapeutics (FATE)
Leerink Partners Maintains Fate Therapeutics(FATE.US) With Buy Rating
Fate Therapeutics' Promising Outlook: Buy Rating on Innovative Cell Therapy Programs FT819 and FT522
Fate Therapeutics (FATE) Gets a Hold From Stifel Nicolaus
Fate Therapeutics: Hold Rating Amidst Steady Q2 Financials and Clinical Progress
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $5 to $10
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $5 to $10
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Achieve Life Sciences (ACHV) and Kezar Life Sciences (KZR)
Fate Therapeutics Analyst Ratings
Fate Therapeutics (FATE) Receives a Buy From Barclays
TD Cowen Reaffirms Their Hold Rating on Fate Therapeutics (FATE)
Fate Therapeutics Analyst Ratings
Fate Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)
Fate Therapeutics: Advancements and Differentiation in Autoimmune and Cancer Therapies Support Buy Rating
Stifel Nicolaus Sticks to Their Hold Rating for Fate Therapeutics (FATE)
Hold Rating on Fate Therapeutics Amid Pending Clinical Data and Strategic Pipeline Focus